Abstract
Background Height has been associated with many clinical traits but whether such associations are causal versus secondary to confounding remains unclear in many cases. To systematically examine this question, we performed a Mendelian Randomization-Phenome-wide association study (MR-PheWAS) using clinical and genetic data from a national healthcare system biobank.
Methods and Findings Analyses were performed using data from the US Veterans Affairs (VA) Million Veteran Program in non-Hispanic White (EA, n=222,300) and non-Hispanic Black (AA, n=58,151) adults in the US. We estimated height genetic risk based on 3290 height-associated variants from a recent European-ancestry genome-wide meta-analysis. We compared associations of measured and genetically-predicted height with phenome-wide traits derived from the VA electronic health record, adjusting for age, sex, and genetic principal components. We found 345 clinical traits associated with measured height in EA and an additional 17 in AA. Of these, 127 were associated with genetically-predicted height at phenome-wide significance in EA and 2 in AA. These associations were largely independent from body mass index. We confirmed several previously described MR associations between height and cardiovascular disease traits such as hypertension, hyperlipidemia, coronary heart disease (CHD), and atrial fibrillation, and further uncovered MR associations with venous circulatory disorders and peripheral neuropathy. As a number of traits associated with genetically-predicted height frequently co-occur with diabetes mellitus and/or CHD, we evaluated effect modification by diabetes and CHD status of genetically-predicted height associations with risk factors for and complications of diabetes and CHD. We found modification of effects of MR associations by diabetes for skin and bone infections and by CHD status for atrial fibrillation/flutter.
Conclusions We conclude that height may be an unrecognized but biologically plausible risk factor for several common conditions in adults. However, more studies are needed to reliably exclude horizontal pleiotropy as a driving force behind at least some of the MR associations observed in this study.
Competing Interest Statement
CJO is a full-time employee of Novartis Institutes of Biomedical Research.
Funding Statement
This work was supported by funding from the US Department of Veterans Affairs MVP program awards MVP001 I01-BX004821 (YH, KC, PWFW) and MVP003/028 I01-BX003362 (CT, PST, KMC, TLA), SR was supported by US Department of Veterans Affairs award IK2-CX001907 and by funds from the Boettcher Foundation Webb-Waring Biomedical Research Program. KEN is supported by R01 DK122503, R01HG010297, R01HL142302, R01HL143885, R01HG009974, and R01DK101855. BFV is grateful to receive support from the NIH/NIDDK (DK101478 and DK126194) and a Linda Pechenick Montague Investigator award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical oversight and human subjects research protocol approval for the MVP were provided by the VA Central Institutional Review Board in accordance with the principles outlined in the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All GWAS summary statistics will be deposited in the database of genotypes and phenotypes (dbGaP) at the time of publication in a peer-reviewed journal.
